65,437 trials
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 — -0.67; -0.06 %A1C — p=<0.001
Sarcoma
Primary: Overall Objective Response — 4; 1 participants
Ductal Breast Carcinoma In Situ · HER2/Neu Positive
Primary: Proliferation (Ki67 IHC) in Ductal Breast Carcinoma In Situ (DCIS)
Sarcoma
Primary: Tumor Response Rate Every 4 Weeks — 4; 1 participants
Tonsillectomy
Primary: Heart Rate (HR) — 120; 121; 107; 121 bpm — p=<0.01
Solid Tumor
Primary: Maximum Tolerated Dose (MTD) of Docetaxel in Combination of Pertuzumab — 75.0 mg/m^2
Coronary Artery Disease
Primary: Composite Rate of Cardiac Death and Target Vessel Myocardial Infarction (MI) — 3.6 percentage of participants
Psoriasis Vulgaris · Psoriasis
Primary: Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week…
GVHD · Ocular Rosacea · Dry Eye Syndrome
Primary: Number of Participants Who Responded to Intense Pulsed Light (IPL) — 5; 2 participants
Parkinson's Disease
Primary: "Off" and "On" Medication Unified Parkinson's Disease Rating III Score (UPDRS) — 48.4; 28.9; 23.52; 22.56 units on a scale — p=<0.001
Type 2 Diabetes
Primary: Change From Baseline in A1C at Week 24 — -0.47; -0.43 Percent
Glaucoma
Primary: Change in Intraocular Pressure — 12.6; 14.4 mm Hg
Breast Cancer · Bone Metastases
Primary: Time to Progression — 317 Days
Bronchial Asthma · Asthma · Status Asthmaticus
Primary: The Primary Endpoint Will be Time to Readiness for Discharge. — 1.74; 1.75 days
Hypertension · Diabetes · Hypercholesterolemia
Primary: Medication Possession Ratio at Baseline — 65.0 percentage of medication possession